Tafluprost
Modify Date: 2025-08-21 10:38:49
Tafluprost structure
|
Common Name | Tafluprost | ||
|---|---|---|---|---|
| CAS Number | 209860-87-7 | Molecular Weight | 452.531 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 552.9±50.0 °C at 760 mmHg | |
| Molecular Formula | C25H34F2O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 288.2±30.1 °C | |
Use of TafluprostTafluprost(AFP-168) is an anti-glaucoma prostaglandin (PG) analog.Target:OthersTafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic patterns [1]. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile [2]. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma. Safety was satisfactory [3]. |
| Name | tafluprost |
|---|---|
| Synonym | More Synonyms |
| Description | Tafluprost(AFP-168) is an anti-glaucoma prostaglandin (PG) analog.Target:OthersTafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic patterns [1]. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect, but also for its good corneal safety profile [2]. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma. Safety was satisfactory [3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 552.9±50.0 °C at 760 mmHg |
| Molecular Formula | C25H34F2O5 |
| Molecular Weight | 452.531 |
| Flash Point | 288.2±30.1 °C |
| Exact Mass | 452.237427 |
| PSA | 75.99000 |
| LogP | 4.23 |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.549 |
| InChIKey | WSNODXPBBALQOF-VEJSHDCNSA-N |
| SMILES | CC(C)OC(=O)CCCC=CCC1C(O)CC(O)C1C=CC(F)(F)COc1ccccc1 |
| Storage condition | -20℃ |
| Tapros |
| MK-2452 |
| 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5Z)- |
| propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate |
| Saflutan |
| AFP-168 |
| Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate |
| Taflotan |
| Tafluprost |
| Isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl}-5-heptenoate |
| UNII-1O6WQ6T7G3 |
| Zioptan |